Tesamorelin
Growth Hormone-Releasing Hormone (1-44) amide
Tesamorelin is an FDA-approved synthetic growth hormone-releasing hormone (GHRH) analog specifically indicated for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. It works by stimulating the pituitary gland to release growth hormone, leading to targeted reduction in visceral adipose tissue through enhanced lipolysis and fat metabolism.
Tesamorelin Dosing Guide
Primary Benefits
- Significant reduction in visceral abdominal fat (15.2% average)
- FDA-approved treatment for HIV-associated lipodystrophy
- Improved body composition and trunk-to-limb fat ratio
- Enhanced growth hormone and IGF-1 levels
- Targeted visceral fat reduction without affecting subcutaneous fat
How It Works
Tesamorelin binds to growth hormone-releasing hormone (GHRH) receptors in the anterior pituitary gland, specifically on somatotroph cells. This binding activates adenylyl cyclase, increasing cyclic adenosine monophosphate (cAMP) levels, which stimulates the synthesis and release of endogenous growth hormone. The released growth hormone then binds to growth hormone receptors in adipose tissue, activating hormone-sensitive lipase and promoting lipolysis, particularly in visceral fat deposits.
Quick Reference
Typical Dosage Range
Standard dose is 2mg daily subcutaneous injection, administered consistently in the evening on an empty stomach. Dose should be taken 30 minutes before eating or 2 hours after eating. Treatment duration typically 6+ months for optimal visceral fat reduction. No dose escalation required - consistent 2mg daily from initiation.
Administration Methods
Subcutaneous injection in abdominal area using provided syringes after reconstituting lyophilized powder with diluent. Rotate injection sites within abdominal region to prevent lipodystrophy. Reconstitute immediately before use - do not store mixed solution. Administer consistently at same time each evening for optimal growth hormone rhythm.
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Tesamorelin (Egrifta) is an FDA-approved prescription medication that should only be used under the supervision of a qualified healthcare provider. Treatment requires proper patient selection, monitoring, and management of potential side effects. Patients must be evaluated for contraindications including active malignancy and diabetic complications. Regular monitoring of glucose levels, IGF-1, and treatment response is essential for safe and effective use.